Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Acute Respiratory Infections

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection

Palivizumab leads to lower hospitalisation for RSV infection compared with placebo (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.49 [0.37, 0.64]
3 studies · 2831 participants
High

Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in hospitalisation for RSV infection compared with motavizumab (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.36 [0.97, 1.9]
2 studies · 7870 participants
Moderate